Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:CASNumber |
1025065-69-3
|
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
terminated |
| gptkbp:developedBy |
SuperGen
|
| gptkbp:endDate |
cardiotoxicity
|
| gptkbp:hasMolecularFormula |
C21H19N5O2
|
| gptkbp:hasSMILES |
C1=CN(N=C1)C2=NC(=C(N=C2N)NC3=CC(=NN3)C4=CC=C(C#N)C=C4)C(=O)N
|
| https://www.w3.org/2000/01/rdf-schema#label |
SGI-1776
|
| gptkbp:intendedUse |
anticancer agent
|
| gptkbp:IUPACName |
4-(3-(4-cyanophenyl)-1H-pyrazol-4-ylamino)-2-(1-methyl-1H-pyrazol-4-ylamino)pyrimidine-5-carboxamide
|
| gptkbp:mechanismOfAction |
PIM kinase inhibitor
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105727
25154816 |
| gptkbp:synonym |
SGI 1776
SGI1776 |
| gptkbp:target |
PIM1
PIM2 PIM3 |
| gptkbp:bfsParent |
gptkb:PIM_1
|
| gptkbp:bfsLayer |
7
|